Abstract
Implement the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) framework (first introduced by Lakdawalla & Phelps (L&P, 2021)) to estimate the comprehensive value of direct-acting antivirals (DAAs) for the treatment of hepatitis C (HCV) compared to peginterferon alfa and ribavirin (PEG/riba), accounting for differential valuations of life years vs. quality of life (QoL), disease severity, and insurance value, in addition to other novel value elements of our generalized cost-effectiveness analysis (GCEA).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
